An exposure–safety analysis to support the dosage of the novel AKT inhibitor capivasertib
Significant exposure-response relationships were identified for safety endpoints when capivasertib was administered to patients with solid tumors suggesting that the intermittent [4/3] schedule is better tolerated than the continuous schedule due to lower total weekly exposure.
Authors
- Carlos Fernández Teruel
- Gaia Schiavon (ORCID: https://orcid.org/0000-0001-9059-8971)
- Diansong Zhou (ORCID: https://orcid.org/0000-0002-2673-1069)
- Marie Cullberg (ORCID: https://orcid.org/0000-0003-1697-972X)
- Ignacio Ferreira González (ORCID: https://orcid.org/0000-0003-3663-3259)
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (South Korea) (KR)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Sweden) (SE)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1007/s00280-025-04775-8
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Astex Pharmaceuticals